COMMUNIQUÉS West-GlobeNewswire

Dr. Falk Pharma and Renexxion Reach Alignment with FDA and EMA on Phase 3 Program for Naronapride in Gastroparesis
21/10/2026
Agencies aligned on trial design, endpoints and safety database; FDA agreed NDA-enabling studies can run in parallel with Phase 3 FREIBURG, Germany and ROSCREA, Ireland, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Dr. Falk Pharma [...]
Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026
21/10/2026
Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS) [...]
Eyonis Invited to Present AI Advances in Lung Cancer Detection and Diagnosis at 50th I-ELCAP Conference
21/10/2026
Two company presentations before leading lung cancer screening researchers will examine malignancy prediction and an integrated approach to AI-assisted diagnosis San Francisco, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Eyonis [...]
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
21/10/2026
Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in [...]
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
21/10/2026
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated [...]
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
21/10/2026
Final pre-MAA package submitted to MHRA on October 20, 2026 Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks U.S. [...]
Integra LifeSciences Reports Third Quarter 2026 Financial Results
21/10/2026
PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending [...]
Vistin Pharma ASA: Invitation to Q3 2026 conference call
21/10/2026
Oslo, Norway, 21 October 2026 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2026 results on Thursday 29th of October 2026. Vistin Pharma will host a conference call for all shareholders and interested [...]
Promising Early Safety Data as Quell Therapeutics Advances QEL-005 – a Novel Engineered nTreg Therapy – to Second Dose Cohort in CHILL Phase 1/2 Trial in Difficult-to-Treat Rheumatoid Arthritis and Systemic Sclerosis
21/10/2026
Safe completion of the first dose cohort in which QEL-005 was well tolerated, with no dose-limiting toxicities (DLTs), no treatment-related adverse events of special interest (AESIs) and no serious adverse events (SAEs [...]
NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051
21/10/2026
STEVENAGE, United Kingdom, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in [...]
KFSH Forecasts Emergency Demand 24 Hours Ahead with AI as Time to See a Physician Falls 42%
21/10/2026
RIYADH, Saudi Arabia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is using artificial intelligence to forecast Emergency Department demand 24 hours ahead, double its [...]
Bioxodes BIOX-101 Phase 2a data show statistically significant reduction in perihematomal edema growth in intracerebral hemorrhage
21/10/2026
First disclosure of new imaging analyses and one-year functional outcome were presented at the World Stroke Congress today Change in normalized hemorrhage volume was significantly lower with BIOX-101 versus standard of [...]
Avance Clinical to Meet European Biotechs at ESMO Congress 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of Excellence
21/10/2026
Executive Medical Director Dr George Peoples to discuss oncology programs from preclinical through Phase II in Madrid ADELAIDE, Australia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO [...]
Kylo Peptides Marks Record Month as Brand Searches Nearly Triple
21/10/2026
Sheridan, Wyoming, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a research peptide supplier, recorded its highest month of brand search interest in September 2026. Estimated US searches [...]
ONWARD Medical Announces the Appointment of Fouad Azzam to its Board of Directors
21/10/2026
Fouad Azzam is a Partner with EQT Life Sciences, bringing extensive experience investing in and supporting fast-growing medical technology and life sciences companies EINDHOVEN, the Netherlands, Oct. 21, 2026 (GLOBE [...]
First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial
21/10/2026
First Patient Treated in the C-FLASH-01 ConformalFLASH ® Clinical Trial Louvain-la-Neuve, Belgium, October 21, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and [...]
Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH®
21/10/2026
Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH ® Louvain-la-Neuve, Belgique, le 21 octobre 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’ [...]
F2G and Shionogi Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in Invasive Aspergillosis in Late-Breaking Oral Presentation at IDWeek 2026
21/10/2026
Oral olorofim was non-inferior to AmBisome ® followed by standard of care (AmBisome ® +SOC), with Day 42 all-cause mortality of 23.8% for olorofim versus 24.3% for AmBisome ® +SOC in patients with invasive aspergillosis [...]
Teknova Announces Pricing of $40 Million Public Offering of Common Stock
21/10/2026
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]

Pages